Last reviewed · How we verify
AK119
At a glance
| Generic name | AK119 |
|---|---|
| Sponsor | Akeso |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients (PHASE1, PHASE2)
- A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer (PHASE1, PHASE2)
- A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors (PHASE1)
- A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects (PHASE1)
- Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Study of AK119 in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |